Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBP-KP01
- Development stage
- Preclinical
- Lead developer
- Locus Biosciences
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Silencing → Gene Therapies, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Editing → Gene Therapies, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous, Intravesical
01
Overview
LBP-KP01 is a precision-engineered bacteriophage cocktail developed to target and eliminate Klebsiella pneumoniae, a bacterial pathogen responsible for complicated and recurrent urinary tract infections (UTIs), including those caused by antibiotic-resistant strains. The product utilizes a dual mechanism of action combining the natural lytic activity of bacteriophages with the DNA-targeting function of an engineered CRISPR-Cas3 system. This approach enables highly specific destruction of K. pneumoniae cells while sparing beneficial bacteria, offering potential advantages over traditional broad-spectrum antibiotics. LBP-KP01 is being developed by Locus Biosciences in partnership with CARB-X and has received funding support for preclinical development and early clinical trials[1][2][5][6].
- Other names
- CRISPR/Cas3-engineered bacteriophage
02
Targets
Klebsiella pneumoniae cell surface structures
Beyond the preview
Go deeper on LBP-KP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBP-KP01.